During the 2018 ACR/ARHP Annual Meeting, the ACR’s Registry Team will hold a RISE user group meeting to showcase the innovative, new RISE dashboard, designed to help maximize your performance scores for MIPS submission. We welcome current RISE users to share their experiences thus far and to be part of the improvement process as we…
What to See in Chicago during the 2018 ACR/ARHP Annual Meeting
With magnificent skylines and a reputation for art, culture and fun, Chicago is a great setting for the 2018 ACR/ARHP Annual Meeting. Here are some must-see places in our host city…
Piclidenoson in Trials for Psoriasis & RA; Plus Duzallo Approved in Europe
New clinical trials are underway to determine the safety and efficacy of piclidenoson for patients with plaque psoriasis and rheumatoid arthritis…
Sessions to Check Out During the 2018 ACR/ARHP Annual Meeting
With more than 450 sessions, the 2018 ACR/ARHP Annual Meeting, is your gateway to global rheumatology education. Here is a preview of a few sessions attendees can look forward to…
Advocates for Arthritis Fly-In Event Benefits Rheumatology Patients
Pendaar Pooyan was diagnosed with juvenile idiopathic arthritis (JIA) in elementary school. He learned to ask for what he needed: use of a computer in class because of wrist pain and a locker that didn’t require him to bend down so far. And he learned to talk about his disease. This helped make participating for…
Bone Mineral Density Most Important Determinant of Fracture Risk
NEW YORK (Reuters Health)—In what is believed to be the largest study investigating genetic and clinical determinants of osteoporotic fracture risk, only a genetic predisposition to low bone mineral density (BMD) had a potential causal role to play. “Notably, genetic predisposition to lower levels of vitamin D and estimated calcium intake from dairy sources were…
Phase 2 Trial Results Suggest Baricitinib Is Effective for SLE
A recent study found that baricitinib improved symptoms of arthritis and rash in patients with active SLE, while maintaining a safety profile consistent with previous findings…
AstraZeneca Lupus Drug Fails to Meet Main Goal in Study
(Reuters)—AstraZeneca’s experimental drug anifrolumab failed to meet its main target in a late-stage clinical study treating patients with moderate to severe lupus, the British drugmaker said on Friday. AstraZeneca said the drug did not meet the main goal in the final-stage of one of the two clinical trials under the TULIP program, failing to show…
Investigators Assess Infection Risk with RA Biologics
Due to a range of factors, determining the precise infection risk posed by new biologic therapies to RA patients is difficult. But progress has been made and health registries may be helpful, said Olivier Lortholary, MD, PhD, during the 2018 EULAR: Annual European Congress of Rheumatology…
Advocate for Prompt Vasculitis Diagnosis & Treatment
Rheumatologists can act as advocates for patients and their families in a way that supports targeting vasculitis early. Here’s how…
- « Previous Page
- 1
- …
- 132
- 133
- 134
- 135
- 136
- …
- 310
- Next Page »